Sequence information
Variant position: 5048 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 5537 The length of the canonical sequence.
Location on the sequence:
DMRRCCFCHEEGDGATDGPA
R LLNLDLDLWVHLNCALWSTE
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human DMRRCCFCHEEGDGATDGPAR LLNLDLDLWVHLNCALWSTE
Mouse DNRRCCFCHEEGDGATDGPAR LLNLDLDLWVHLNCALWSTE
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
Chain
1 – 5537
Histone-lysine N-methyltransferase 2D
Zinc finger
5029 – 5069
C2HC pre-PHD-type 2
Literature citations
MLL2 and KDM6A mutations in patients with Kabuki syndrome.
Miyake N.; Koshimizu E.; Okamoto N.; Mizuno S.; Ogata T.; Nagai T.; Kosho T.; Ohashi H.; Kato M.; Sasaki G.; Mabe H.; Watanabe Y.; Yoshino M.; Matsuishi T.; Takanashi J.; Shotelersuk V.; Tekin M.; Ochi N.; Kubota M.; Ito N.; Ihara K.; Hara T.; Tonoki H.; Ohta T.; Saito K.; Matsuo M.; Urano M.; Enokizono T.; Sato A.; Tanaka H.; Ogawa A.; Fujita T.; Hiraki Y.; Kitanaka S.; Matsubara Y.; Makita T.; Taguri M.; Nakashima M.; Tsurusaki Y.; Saitsu H.; Yoshiura K.; Matsumoto N.; Niikawa N.;
Am. J. Med. Genet. A 161A:2234-2243(2013)
Cited for: VARIANTS KABUK1 ARG-1376; CYS-1423; GLY-1445; PHE-1526; CYS-5030; GLY-5040; CYS-5048; HIS-5048; GLN-5154; HIS-5179; ARG-5189 AND GLN-5351;
MLL2 mutation detection in 86 patients with Kabuki syndrome: a genotype-phenotype study.
Makrythanasis P.; van Bon B.W.; Steehouwer M.; Rodriguez-Santiago B.; Simpson M.; Dias P.; Anderlid B.M.; Arts P.; Bhat M.; Augello B.; Biamino E.; Bongers E.M.; Del Campo M.; Cordeiro I.; Cueto-Gonzalez A.M.; Cusco I.; Deshpande C.; Frysira E.; Izatt L.; Flores R.; Galan E.; Gener B.; Gilissen C.; Granneman S.M.; Hoyer J.; Yntema H.G.; Kets C.M.; Koolen D.A.; Marcelis C.L.; Medeira A.; Micale L.; Mohammed S.; de Munnik S.A.; Nordgren A.; Psoni S.; Reardon W.; Revencu N.; Roscioli T.; Ruiterkamp-Versteeg M.; Santos H.G.; Schoumans J.; Schuurs-Hoeijmakers J.H.; Silengo M.C.; Toledo L.; Vendrell T.; van der Burgt I.; van Lier B.; Zweier C.; Reymond A.; Trembath R.C.; Perez-Jurado L.; Dupont J.; de Vries B.B.; Brunner H.G.; Veltman J.A.; Merla G.; Antonarakis S.E.; Hoischen A.;
Clin. Genet. 84:539-545(2013)
Cited for: VARIANTS KABUK1 HIS-170; LEU-170; GLN-647; ARG-1380; ARG-1471; ARG-3876; SER-3897; CYS-5030; CYS-5048; HIS-5048; CYS-5214; TRP-5432 AND PHE-5498; VARIANTS LEU-2557; LEU-2652 AND PRO-4010;
Disclaimer:
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.